Lawrence D. Piro - Concepedia

Author

Lawrence D. Piro

Also Known As

L D Piro, L Piro, L. D. Piro, L. Piro, L.D. Piro, LAWRENCE D. PIRO, Lawrence D Piro, Lawrence D. Piro, Lawrence Piro, Luigia Piro

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Scripps Health Scripps Clinic Scripps Research Institute The Ohio State University Cedars-Sinai Medical Center

About

Lawrence D. Piro is an author at Scripps Health specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	896
2	Immunology	9	9	810
3	Health Sciences	4	4	166
4	Cell Biology	2	2	165
5	Allergy	1	1	38

Lawrence D. Piro

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Lasting Remissions in Hairy-Cell Leukemia Induced by a Single Infusion of 2-Chlorodeoxyadenosine Lawrence D. Piro, Carlos J. Carrera, Dennis A. Carson, New England Journal of Medicine	1990	514
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Lawrence D. Piro, Christine A. White, A.J. Grillo-López, Annals of Oncology Lymphoid NeoplasiaMedicineImmunologyAnti-cd20 Monoclonal AntibodyImmune Checkpoint Inhibitor	1999	368
Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment Alan Saven, Carol Burian, James A. Koziol, Blood	1998	316
2-Chlorodeoxyadenosine treatment of low-grade lymphomas. Andrea Kay, Alan Saven, C J Carrera, Journal of Clinical Oncology	1992	169
Combination Chemotherapy in Refractory Immune Thrombocytopenic Purpura Michael L. Figueroa, Jane A. Gehlsen, Denis B. Hammond, New England Journal of Medicine	1993	137
Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. C J Carrera, Chihiro Terai, Martin Lotz, Journal of Clinical Investigation ImmunotoxicologyImmunologyBlood CellCell DeathContinuous Cldado Infusion	1990	125
2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. Alan Saven, Robert H. Lemon, Michael P. Kosty, Journal of Clinical Oncology	1995	119
A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma Khuda Dad Khan, Christos Emmanouilides, Don M. Benson, Clinical Cancer Research	2006	100
Enhanced Survival Associated with Vitiligo Expression during Maintenance Biotherapy for Metastatic Melanoma Peter D. Boasberg, Dave S.�B. Hoon, Lawrence D. Piro, Journal of Investigative Dermatology Vitiligo ExpressionMedicineMelanomaImmunologyMetastatic Melanoma	2006	98
2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside Ernest Beutler, Lawrence D. Piro, Alan Saven, Leukemia & lymphoma/Leukemia and lymphoma	1991	96

Page 1